Type 1 hepatorenal syndrome (HRS) is the most high-risk type of renal failure in patients with cirrhosis. Terlipressin and albumin are effective treatments for type 1 HRS. However, the effects of acute on chronic liver failure (ACLF) grade on response to treatment are not clear. We aimed to identify factors associated with response to treatment with terlipressin and albumin in patients with type 1 HRS (reduction in serum level of creatinine to below 1.5 mg/dL at the end of treatment) and factors associated with death within 90 days of HRS diagnosis (90-day mortality).
T ype 1 hepatorenal syndrome (HRS) is one of the most life-threatening complications in patients with decompensated cirrhosis. 1 It is characterized by a rapidly progressive acute renal failure, frequently triggered by bacterial infections or other precipitating events, and is associated with very high short-term mortality rate.
The pharmacological treatment with terlipressin (or noradrenaline) and albumin is the most effective treatment of type 1 HRS. [2] [3] [4] [5] It was introduced in the 1990s, soon after the formulation of the peripheral arterial vasodilation hypothesis, which proposed HRS as the extreme expression of a severe splanchnic arterial vasodilation and impairment in circulatory function. 6 Subsequent studies in patients with spontaneous bacterial peritonitis (SBP) revealed that HRS occurs in the setting of marked reduction in cardiac output proving for the first time that HRS results from a more complex pathogenesis. 7 In addition to arterial vasodilation, left ventricular dysfunction is also a major contributor. Therefore, resolution of HRS after pharmacological treatment was proposed to be due to a combined effect of terlipressin on systemic vascular resistance and of albumin on effective circulating blood volume and cardiac output. This strategy enables a resolution of HRS in 40%-70% of patients. Important predictors of complete response and mortality seem to be serum bilirubin, serum creatinine (sCr) concentration and the early response to treatment. 8, 9 The characterization of acute-on-chronic liver failure (ACLF) by the Canonic study in 2013, has deeply modified our concepts on the pathogenesis of HRS. 10 ACLF is a syndrome defined by acute decompensation of cirrhosis, single or multiple (2 or more) organ failures, severe systemic inflammation and very high short-term mortality rate. 10 Type 1 HRS is, therefore, a special form of ACLF. Patients with decompensated cirrhosis without ACLF present severe chronic systemic inflammation probably as consequence of continuous translocation of bacteria and bacterial products from gut microbiota to the systemic circulation 11 . ACLF develops when there is a further acute increase in systemic inflammation in response to pro-inflammatory triggers (ie, bacterial infections, acute liver injury, or, in patients without identifiable triggers, probably an acute burst of bacterial translocation). The current belief is that systemic inflammation is the common mechanism of acute decompensation and organ dysfunction/failure(s) in patients with decompensated cirrhosis. 11 As such, a higher degree of systemic inflammation was associated with a higher number of organ failures and, thus, with a higher grade of ACLF. 10, 12 This profound change of the pathophysiological background may affect the efficacy of the treatment of type 1 HRS by terlipressin plus albumin in patients with ACLF. However, the potential negative impact of the degree of ACLF on the response to the treatment with terlipressin and albumin in patients with type 1 HRS has been evaluated only in a very small series of patients with sepsis induced HRS. 13 The aim of the current study was, therefore, to assess the impact of severity of ACLF on the renal response to terlipressin and albumin in patients with HRS. The secondary aim of the study was to assess predictors of 90-day mortality
Patients and Methods

Patients
The study includes 4 different cohorts of consecutive patients with HRS treated with terlipressin and albumin. Some patients were included in prospective investigations already published. 4, 5, 10, 13 The first cohort includes patients evaluated from February 2007 to January 2016 at the University Hospital of Padova (Italy), the second cohort includes patients evaluated from July 2009 to December 2015 at the Liver Unit, Hospital Clinic of Barcelona (Spain), the third cohort includes patients recruited from February to September 2011 in the Canonic study, and the fourth cohort included patients treated from 2010 to 2015 at the University Hospital of Munster (Germany). The protocol was approved by the local ethics committee at each center.
Inclusion criteria were (1) diagnosis of cirrhosis according to histological, clinical, biochemical, ultrasonographic, or endoscopic findings; (2) diagnosis of type 1 HRS according to the International Club of Ascites criteria 14 ; (3) !18 years of age. Exclusion criteria were (1) hepatocellular carcinoma beyond Milan criteria; (2) extrahepatic malignancy; (3) septic or hypovolemic shock; (4) proteinuria>500 mg/24 hours; (5) hematuria>50 red blood cells per high-resolution field; (6) abnormal renal ultrasound; (7) severe extrahepatic disease (congestive heart failure stage New York Heart Association functional class !II, chronic obstructive pulmonary disease stage GOLD !2); (8) treatment of HRS with midodrine, octreotide and albumin, or norepinephrine and albumin; and (9) previous liver transplant.
Definitions
Type 1 HRS was defined according to International Club of Ascites criteria 14 : (1) an increase in sCr of at least 100% in the previous 14 days up to values above 2.5 mg/dL in a patient with cirrhosis and ascites; (2) no response (sCr>2 mg/dL) after diuretic withdrawal and albumin expansion at the dose of 1g/kg/day for 2 days; (3) absence of signs of parenchymal kidney damage (24-hour proteinuria <500 mg; red blood cells in urine <50 per high-resolution field; normal renal ultrasonography); and (4) absence of shock or treatment with nephrotoxic drugs (ie, iodine contrast media, nonsteroidal anti-inflammatory drugs, aminoglycosides).
Resolution of HRS (or response to treatment) was defined as a reduction of sCr to <1.5 mg/dL during treatment.
ACLF was defined according to the European Association for the Study of the Liver-Chronic Liver Failure (CLIF) consortium. 10 Extrahepatic organ failures were defined by the Chronic Liver Failure organ failure score, which is a simplified version of the original CLIF-SOFA score. 15 More in detail, liver failure was defined as a bilirubin !12 mg/dL; coagulation failure as an international normalized ratio !2.5; brain failure as hepatic encephalopathy grade !3 (West Haven criteria); respiratory failure as an SpO 2 /FiO 2 ratio 214 or a PaO 2 /FiO 2 ratio 200 or the need for mechanical ventilation; circulatory failure is defined by as the need for vasopressor therapy to achieve an adequate mean arterial pressure (MAP).
ACLF was graded as follows: ACLF-1: HRS alone; ACLF-2: HRS and 1 extrarenal organ failure; ACLF-3: HRS and 2 or more extrarenal organ failures. Therefore, by definition, all patients with type 1 HRS included had at least ACLF-1.
Design of the Study
Terlipressin was administered at a starting dose of 2-3 mg/day administered as intravenous boluses (0.5 mg every 4-6 hours) or continuous intravenous infusion. The dose of terlipressin was increased in a stepwise manner up to a maximum of 12 mg/day in patients without early response to treatment (decrease of sCr to more than 25% of pretreatment value after 48-72 hours of treatment). In patients developing severe side effects potentially related to terlipressin the drug was withdrawn. Albumin was administered at a loading dose of 1 g/kg/day (corresponding to the second day of differential diagnosis of HRS) and 20-40 g/day the subsequent days. The treatment was continued until resolution of HRS (sCr <1.5 mg/dL) or the appearance of severe side effects (pulmonary edema, cardiac arrhythmia or severe ischemic complications) up to a maximum of 15 days.
Nonresponders to treatment were managed according to standard of care. Renal replacement therapy was considered an option when indicated only in patients who were candidates to liver transplantation (LT).
Clinical and laboratory characteristics were collected on the day of first administration of terlipressin and albumin (baseline data), on the third day of treatment and at the end of treatment. Patients were followed up until death, LT or for a maximum of 90 days.
Statistical Analysis
Results are presented as frequencies and percentages for categorical variables, means and SDs for normally distributed continuous variables and median and interquartile range for not normally distributed continuous variables. Not normally distributed variables were logtransformed when necessary. In univariate analyses, the chi-square test was used for categorical variables, Student's t test or analysis of variance for normal continuous variables and Mann-Whitney or KruskalWallis test for not normally distributed continuous variables. To assess the response to terlipressin and albumin treatment, logistic regression models were carried out. Factors showing a clinically and statistically significant association to the outcome in univariate analyses were selected for the initial model. The final models were fitted by using a step-wise forward method based on Likelihood Ratios with the same significance level (P < .05) for entering and dropping variables. Using the final model an estimated probability of response after treatment was calculated. The proportional-hazards model for Competing-Risks proposed by Fine and Gray 16 was used to assess the presence of independent factors of mortality. This model was chosen to account for LT as an event competing with mortality. In all statistical analyses, significance was set at P < .05. Analyses were done with SPSS (version 23.0; SPSS, Inc. Chicago, IL) and SAS (version 9.4; SAS Institute Inc.; Cary, NC) statistical packages.
Results
Study Population
Two-hundred and ninety-eight patients with cirrhosis and HRS were included in the study. Supplementary Table 1 illustrates the clinical characteristics of the patients. HRS was associated with bacterial infections in 169 patients (68 with SBP). The most common extrarenal organ failure was liver failure (27%), followed by coagulation failure (13%), brain failure (7%), and respiratory failure (2%). A total of 179 patients (60%) had ACLF-1, 91 (31%) ACLF-2, and 28 (9%) ACLF-3. The characteristics of the 4 cohorts of patients studied are shown in Supplementary Table 2 .
Resolution of HRS
Patients were treated for a median of 8 days and the median cumulative dose of terlipressin was 24 mg (interquartile range: 14-42 mg). Resolution of HRS was observed in 53% of the patients. Responders showed significantly lower baseline serum bilirubin (3.3 vs 4.8 mg/dL; P ¼ .003), international normalized ratio (1.6 vs 1.8; P ¼ .004) and sCr (2.7 vs 3.2 mg/dL; P < .001) than nonresponders (Table 1) . Response rate showed a stepwise decrease from grade 1 to grade 3 ACLF (60%, 48%, and 29% for ACLF-1, ACLF-2, and ACLF-3, respectively; P < .001).
MAP increased significantly during treatment (79 vs 86 mm Hg at day 3; P < .001), but no difference was found in delta MAP at day 3 between responders and nonresponders. Unexpectedly, the delta MAP at day 3 increased in a stepwise fashion from grade 1 to grade 3 ACLF (5, 6 and 13 mm Hg, respectively; P ¼ .014). The increase in MAP was retained in responders while MAP dropped in nonresponders at the end of treatment. The delta decrease in sCr at day 3 was significantly higher in responders than in nonresponders (Table 1) .
Complete sequential data on serum albumin concentration were available in 175 patients. Although serum albumin increased significantly (P < .001), the median delta increase was very small (0.2 g/dl; Supplementary Figure 1 ) and the delta increase of albumin on day 3 was not significantly different between responders and nonresponders.
In the multivariate analysis, only baseline sCr (OR: 0.23; P ¼ .001) and ACLF grade (OR: 0.63; P ¼ .01) were found to be independent predictors of response to treatment. Figure 1 shows the expected probability of HRS resolution according to baseline sCr concentration and ACLF grade. The probability of HRS resolution decreased stepwise from ACLF-1 to ACLF-3 at any level of sCr. According to the final model, the probability of response to terlipressin plus albumin can be estimated by the following equation: We also explored predictors of response to treatment using variable available on day 3. Again, ACLF grade on day 3 (OR: 0.55; 95% CI: 0.35-0.86; P ¼ .009) and the delta sCr (OR: 0.43; 95% CI: 0.28-0.67; P < .001) were found to be the only independent predictors of response to terlipressin and albumin. Interestingly, the expected probability of HRS resolution was very low (z10%) in patients with ACLF grade 3 and no improvement in sCr (Supplementary Figure 2) .
Survival
During the 90-day follow-up 119 patients died (40%), 50 were transplanted (17%), 123 completed follow-up (41%), and 6 patients were lost to follow-up (2%). The cumulative incidence of 90-day mortality was 41%. As expected, nonsurvivors were older and had a significant worse liver function than survivors ( Table 2) . Scores of liver disease such as MELD, Child-Pugh and CLIF-C ACLF score were significantly higher and serum sodium was significant lower in nonsurvivors than in survivors. There was a nonsignificant trend towards a higher white blood cells count in nonsurvivors than in survivors. The cumulative incidence of 90-day mortality increased in a stepwise fashion according to ACLF grade (30%, 50%, and 79% for ACLF-1, ACLF-2 and ACLF-3, respectively; P < .001; Figure 2A) . In univariate analysis, response to treatment was also a main determinant of survival. Indeed, the cumulative incidence of mortality was Patients transplanted (n ¼ 50) or lost to follow-up (n ¼ 6) were excluded from this analysis.
significantly lower in responders than in nonresponders (28 vs 57%; P < .001; Figure 2B ). More in detail, in patients with ACLF grade 1 and 2, responders had a significant decrease in 90-day mortality than nonresponders (20% vs 47%, P < .001; 40 vs 60%, P ¼ .018; for grade 1 and 2, respectively), while no difference was observed in patients with ACLF grade 3 (71% vs 80%; P ¼ .201). However, a trend towards an improvement in 28-day mortality was observed in responders vs nonresponders with ACLF grade 3 (43% vs 80%; P ¼ .063). Interestingly, mortality rate increased according to ACLF grade both in responders and nonresponders ( Figure 3A and B).
In multivariate analysis, age (hazard ratio [HR]: 1.05; 95% confidence interval [CI]: 1.03-1.07; P < .001), white blood cells count (HR: 1.51, 95% CI: 1.12-2.02); P ¼ .006, ACLF grade (HR: 2.06; 95% CI: 1.54-2.75; P < .001), and response to treatment (yes or no; HR: 0.41; 95% CI: 0.29-0.60; P < .001) were found to be independent predictors of 90-day mortality. When CLIF-C ACLF score was included in the model, it was found to be an independent predictor of survival (HR:
1.09; P < .001) together with the response to treatment (HR: 0.44; P < .001).
Side Effects
Detailed information about side effects were available in 241 patients (Table 3) . A total of 110 patients (46%) developed side effects likely related to treatment with terlipressin and albumin. The most common side effects were diarrhea and abdominal pain, followed by intestinal ischemia, peripheral ischemia, pulmonary edema and angina. The treatment with terlipressin and albumin was withheld in 48 patients (20%).
Discussion
Our study, which represents the largest investigation on the pharmacological treatment of HRS, confirms the 2 major findings so far described. The first is that the combination of terlipressin and albumin is effective resolving HRS in approximately 50% of patients. The second is that baseline sCr or early improvement in sCr are accurate predictors of treatment response and patient survival. It has been proposed that once severe HRS develops, ischemic tubular lesions or renal hypoperfusion (resulting from imbalance between the intrarenal synthesis of vasoconstrictor and vasodilator molecules) maintain or worsen renal failure independent of any potential improvement in cardiovascular function due to terlipressin/albumin. 17 Given this, current clinical guidelines propose that early detection and treatment of HRS would increase the rate of treatment response and survival in patients with ongoing HRS. 18 The most outstanding observation of our study is that severity of ACLF, as estimated by the number of extrarenal organ failures, is an additional important factor predicting treatment response in patients with HRS. The rate of resolution of HRS was 60% in patients without extrarenal organ failure (ACLF-1); 48% in patients with 1 extrarenal organ failure (ACLF-2), and only 29% in patients with 2 or more extrarenal organ failures (ACLF-3).
It is possible that cholestasis may be responsible for direct tubular damage in patients with liver failure. 19 However, a recent study by Clària et al 12 suggests that inflammatory markers may have an important role in the pathogenesis of ACLF. They measured plasma levels of cytokines and chemokines as markers of systemic inflammation and the plasma concentration of renin and copeptin (a precursor of antidiuretic hormone) as markers of systemic circulatory dysfunction in a large series of patients with decompensated cirrhosis with and without ACLF. There was a significant increase in plasma levels of both types of markers in patients with ACLF than in patients without ACLF. 12 The strength of the association was stronger for biomarkers of systemic inflammation. Furthermore, plasma cytokine levels, but neither renin nor copeptin, increased stepwise with ACLF grade. Finally, the clinical course (resolution, improvement, steady course, or worsening of ACLF) correlated significantly with markers of systemic inflammation but not with circulatory dysfunction. 12 Our interpretation of these findings is that, although both systemic inflammation and systemic circulatory dysfunction participate in the pathogenesis of ACLF (and HRS), systemic inflammation is the main driver of the syndrome. It is well known that systemic inflammation can reduce organ perfusion as consequence of arterial vasodilation and impaired left ventricular function. It can also impair renal and extrarenal organ function through direct deleterious effects of inflammatory mediators on essential tissue and cell homeostatic mechanisms, including local microcirculation, mitochondrial function and apoptosis. 20 Our results suggest that this pathophysiological interpretation may also offer a rational explanation for our findings. In patients with HRS and ACLF-1, who have moderate increase in systemic inflammation over the chronic inflammation of decompensated cirrhosis, cardiocirculatory dysfunction and renal hypoperfusion may have a significant role in ACLF development. Therefore, these patients may be more likely to respond to terlipressin and albumin. In contrast, systemic inflammation is more intense in patients with ACLF-2 and particularly with ACLF-3. The predominant mechanism in these patients might be a generalized increase in microcirculatory and mitochondrial dysfunction and cell death; disorders that cannot be sufficiently reversed by improving systemic circulatory function. Indeed, despite the fact that increase in MAP on day 3 was higher in patients with ACLF-3 than those with lower grades of ACLF, the rate of HRS reversal decreased.
The combination of the 2 major predictors of response into 2 prognostic diagrams ( Figure 1 and Supplementary Figure 2) shows the second important finding of our study. Severity of ACLF influenced treatment response independent of the sCr level, thus supporting the important role played by the underlying pathophysiological processes on the effectiveness of terlipressin and albumin. These data as well as the effects of HRS reversal on survival may have important implications for clinical practice, in particular in patients with ACLF-3. In fact, the reversal of HRS had a modest short-term survival benefit in patients with ACLF-3. Thus, the reversal of HRS can be relevant for patients with ACLF-3 who are eligible for liver transplantation while it may be pointless in those who are not. Therefore, the decision to pursue aggressive management of patients with ACLF-3 who otherwise are ineligible for liver transplantation should be individualized taking into account several factors, including the patient's will. As in previous studies, early renal response to treatment (delta sCr concentration at day 3) was an accurate predictor of HRS resolution. We, however, did not observe significant differences in delta MAP or delta serum albumin concentration at day 3 and at the end of treatment in patients with or without treatment response. Another interesting observation was that the increase of serum albumin concentration at the end of treatment was minor in the 2 groups despite of a administration of intravenous albumin (an initial dose of 1 g/kg of body weight, followed by 20-40 g/day during treatment). Therefore, it is very likely that the current pharmacological treatment of HRS is underpowered in relation with the albumin dosage, which, in contrast to terlipressin, is not adjusted to response.
As expected and confirming previous studies, age and response to treatment were independent predictors of survival in patients with HRS. 2, 4, 5 Other predictors were the baseline white blood cells count, which is a sensitive marker of systemic inflammation in patients with ACLF, and the ACLF grade. Interestingly, mortality rate increased from ACLF-1 to ACLF-3 in patients regardless of treatment response, indicating that severity of ACLF predict survival more accurately than treatment response. 21 Remarkably, patients with ACLF-2 and ACLF-3 had poor prognosis even if they responded to terlipressin and albumin, highlighting the need to develop new treatments for these patients.
In summary, severity of renal failure and ACLF grade are independent predictors of therapeutic response to terlipressin and albumin in patients with HRS. Age, baseline white blood cells count, baseline ACLF grade, and therapeutic response are independent predictors of survival. These data indicate that the grade of systemic inflammation and the presence and number of extrarenal organ failure(s) have a great impact on the clinical course in patients with HRS. New treatments should be explored for patients with type 1 HRS looking at systemic inflammation as a potential target.
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